Monte G, Mezdour H
Recenti Prog Med. 1993 Dec;84(12):855-63.
Lipoprotein(a) represents a cholesterol ester, LDL-like particle with apo B-100 linked to apo (a). Lp(a) is a fascinating subject of research because of its presumed association with atherosclerotic cardiovascular disease. The reported results do not encourage optimism. Drugs like niacin or fibrates when used alone have been attended by mixed results. Neither clofibrate nor bezafibrate, which reduce the VLDL concentration, affect LP(a) levels. Neither the ion-exchange resin cholestyramine, nor the HMG CoA reductase inhibitor lovastatin reduce the serum concentration of Lp(a). But, we must keep in mind that drugs used to lower plasma Lp(a) levels were designed for apo B and not apo B-apo(a) containing particles. Thus, it may be necessary to develop drugs specifically targeted to Lp(a).
脂蛋白(a)是一种胆固醇酯，是一种类似低密度脂蛋白（LDL）的颗粒，其载脂蛋白B-100与载脂蛋白(a)相连。由于推测脂蛋白(a)与动脉粥样硬化性心血管疾病有关，它是一个引人入胜的研究课题。报道的结果并不令人乐观。单独使用烟酸或贝特类药物等药物，结果好坏参半。降低极低密度脂蛋白（VLDL）浓度的氯贝丁酯和苯扎贝特都不会影响脂蛋白(a)水平。离子交换树脂考来烯胺和HMG CoA还原酶抑制剂洛伐他汀都不会降低血清脂蛋白(a)浓度。但是，我们必须记住，用于降低血浆脂蛋白(a)水平的药物是针对载脂蛋白B设计的，而不是针对含有载脂蛋白B-载脂蛋白(a)的颗粒。因此，可能有必要开发专门针对脂蛋白(a)的药物。
